RS20050228A - Upotreba derivata 4-piridilmetil- ftalazina za proizvodnju leka za lečenje mijelodisplastičnih sindroma - Google Patents

Upotreba derivata 4-piridilmetil- ftalazina za proizvodnju leka za lečenje mijelodisplastičnih sindroma

Info

Publication number
RS20050228A
RS20050228A YUP-2005/0228A YUP20050228A RS20050228A RS 20050228 A RS20050228 A RS 20050228A YU P20050228 A YUP20050228 A YU P20050228A RS 20050228 A RS20050228 A RS 20050228A
Authority
RS
Serbia
Prior art keywords
pyridylmethyl
combination
treatment
phthalazine
vitamin
Prior art date
Application number
YUP-2005/0228A
Other languages
English (en)
Serbian (sr)
Inventor
The Arizona Board of Regents on behalf of the University of Arizona
Original Assignee
Novartis Ag.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag., filed Critical Novartis Ag.,
Publication of RS20050228A publication Critical patent/RS20050228A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
YUP-2005/0228A 2002-09-24 2003-09-23 Upotreba derivata 4-piridilmetil- ftalazina za proizvodnju leka za lečenje mijelodisplastičnih sindroma RS20050228A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41317602P 2002-09-24 2002-09-24
PCT/EP2003/010578 WO2004028542A1 (en) 2002-09-24 2003-09-23 Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes

Publications (1)

Publication Number Publication Date
RS20050228A true RS20050228A (sr) 2007-08-03

Family

ID=32043216

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0228A RS20050228A (sr) 2002-09-24 2003-09-23 Upotreba derivata 4-piridilmetil- ftalazina za proizvodnju leka za lečenje mijelodisplastičnih sindroma

Country Status (22)

Country Link
US (1) US20060128716A1 (enExample)
EP (1) EP1545534B1 (enExample)
JP (1) JP2006502195A (enExample)
KR (1) KR20050074450A (enExample)
CN (1) CN100372535C (enExample)
AT (1) ATE359789T1 (enExample)
AU (1) AU2003299065B2 (enExample)
BR (1) BR0314647A (enExample)
CA (1) CA2499738A1 (enExample)
CR (1) CR7754A (enExample)
DE (1) DE60313344T2 (enExample)
EC (1) ECSP055700A (enExample)
ES (1) ES2285251T3 (enExample)
HR (1) HRP20050281A2 (enExample)
MX (1) MXPA05003161A (enExample)
NO (1) NO20051936L (enExample)
PL (1) PL374696A1 (enExample)
PT (1) PT1545534E (enExample)
RS (1) RS20050228A (enExample)
RU (1) RU2353364C2 (enExample)
WO (1) WO2004028542A1 (enExample)
ZA (1) ZA200502212B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407683T1 (de) * 1997-10-15 2008-09-15 Polarx Biopharmaceuticals Inc Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von multiplen myelom
WO2007030582A2 (en) 2005-09-09 2007-03-15 Bristol-Myers Squibb Company Acyclic ikur inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132458B2 (en) * 1994-08-10 2006-11-07 Chemaphor Inc. Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
RU2136308C1 (ru) * 1994-11-16 1999-09-10 Жемчугов Владислав Евгеньевич Стимулятор роста костно-мозговых клеток человека
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CA2366857C (en) * 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
CA2393252A1 (en) * 1999-12-06 2001-06-07 Paul Calabresi Use of methylol-containing compounds to treat tumors

Also Published As

Publication number Publication date
AU2003299065B2 (en) 2006-10-26
JP2006502195A (ja) 2006-01-19
US20060128716A1 (en) 2006-06-15
ATE359789T1 (de) 2007-05-15
ECSP055700A (es) 2005-08-11
CN1684684A (zh) 2005-10-19
NO20051936L (no) 2005-06-23
RU2005112711A (ru) 2006-02-27
CR7754A (es) 2005-12-02
DE60313344D1 (de) 2007-05-31
PL374696A1 (en) 2005-10-31
WO2004028542A1 (en) 2004-04-08
ZA200502212B (en) 2006-02-22
CN100372535C (zh) 2008-03-05
ES2285251T3 (es) 2007-11-16
DE60313344T2 (de) 2008-01-03
CA2499738A1 (en) 2004-04-08
HRP20050281A2 (en) 2006-07-31
BR0314647A (pt) 2005-08-02
EP1545534A1 (en) 2005-06-29
MXPA05003161A (es) 2005-09-12
EP1545534B1 (en) 2007-04-18
KR20050074450A (ko) 2005-07-18
AU2003299065A1 (en) 2004-04-19
RU2353364C2 (ru) 2009-04-27
PT1545534E (pt) 2007-06-22

Similar Documents

Publication Publication Date Title
EP1339458B1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
JP2013231086A (ja) 化学療法の強化方法
US20110070232A1 (en) Combination Therapy with an Antitumor Alkaloid
EP1385522B1 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
AU2002308218A1 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
RU2730998C2 (ru) Композиции форболовых эфиров и способы их применения для лечения или уменьшения продолжительности цитопении
MXPA04006822A (es) Combinaciones que comprenden epotilonas y anti-metabolitos.
RS20050228A (sr) Upotreba derivata 4-piridilmetil- ftalazina za proizvodnju leka za lečenje mijelodisplastičnih sindroma
US20110009335A1 (en) Anticancer Treatments
AU2006271650B2 (en) Combination of a pyrimidylaminobenzamide and an MTOR kinase inhibitor
US20090233939A1 (en) Treatment of amm
JP2006502195A5 (enExample)
ZA200306404B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative.
HK1062266B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative